本报讯 （记者梁傲男）1月22日，认养一头牛正式官宣演员赵丽颖成为品牌代言人。此次合作，不仅是"国民演员"与"新国 民品牌"的默契牵手，更是品牌"产业深耕"与代言人"专业沉淀"的精神共振，双方将一同继续诠释长期主义的价值。 赵丽颖凭借二十年稳扎稳打的从艺之路，以《知否知否应是绿肥红瘦》《风吹半夏》等多部深入人心的国民级作品和扎实 的演技，赢得了跨年龄、跨地域观众的广泛喜爱，其专业、坚韧、不断精进的公众形象深入人心。特别是2026年初热播的《小 城大事》，进一步强化了她真切、务实的国民认知。这与认养一头牛坚持十二年深耕全产业链、稳扎稳打成长为新国民品牌的 路径高度契合。认养一头牛表示，选择赵丽颖正是基于彼此精神内核的深度认同与信任，是一次真正意义上的"双向奔赴"。 此次携手国民级品牌代言人，也是认养一头牛对自身产品力和品牌力的自信表达。 目前其产业布局已具规模效应。全国10座奶牛牧场、4座肉牛牧场、奶牛存栏超10万头、肉牛存栏超3万头，奶源自给率稳 定在95%以上。牧场精细化管理的成效直接体现在生产效率上：2024年，其成母牛年单产达13.81吨，位列全国第二。配合自建 的2座乳制品工厂和1座肉牛屠宰加工场，认 ...

2026.01. 22 记者今日在兰特黎斯官网查询时，未看到相关召回公告。据报道，此次召回属于预防性召回，法国相关部门尚未收到食用涉事产品后发生不良反应 的报告。 此前，新加坡食品局（SFA）也发布公告，召回两批次婴幼儿配方奶粉，其中包括另一家法国食品企业旗下的多美滋婴儿配方奶粉。 新加坡食品局公布的信息显示，蜡样芽孢杆菌毒素由蜡样芽孢杆菌菌株产生，可引起恶心、呕吐、腹部痉挛和腹泻等症状。症状通常在食用受影响 食物后30分钟到6小时内出现，一般在24小时内消失。弱势人群，如婴儿和免疫力低下者，出现并发症的风险更高。目前，国际上尚未制定蜡样芽 孢杆菌毒素的可接受水平标准。 微信编辑 | 苏小 本文字数：705，阅读时长大约1分钟 作者 | 第一财经 栾立 封图 | AI生成 近期，全球多起婴幼儿配方奶粉召回事件引发行业关注。据新华社报道，法国知名乳企兰特黎斯（Lactalis）宣布在法国、中国、西班牙等18个国 家和地区召回多批次婴幼儿配方奶粉，原因是相关产品可能含有蜡样芽孢杆菌毒素，存在引发腹泻和呕吐等风险。 1月22日，海关总署发布消费提示称，目前我国暂未发现兰特黎斯（Lactalis）旗下召回的Picot ...

蜡样芽孢杆菌毒素的影响仍在持续。 近期，全球多起婴幼儿配方奶粉召回事件引发行业关注。据新华社报道，法国知名乳企兰特黎斯（Lactalis）宣布在法国、中国、西班牙等18个国家和地区 召回多批次婴幼儿配方奶粉，原因是相关产品可能含有蜡样芽孢杆菌毒素，存在引发腹泻和呕吐等风险。 新加坡食品局公布的信息显示，蜡样芽孢杆菌毒素由蜡样芽孢杆菌菌株产生，可引起恶心、呕吐、腹部痉挛和腹泻等症状。症状通常在食用受影响食物后30 分钟到6小时内出现，一般在24小时内消失。弱势人群，如婴儿和免疫力低下者，出现并发症的风险更高。目前，国际上尚未制定蜡样芽孢杆菌毒素的可接 受水平标准。 记者今日在兰特黎斯官网查询时，未看到相关召回公告。据报道，此次召回属于预防性召回，法国相关部门尚未收到食用涉事产品后发生不良反应的报告。 此前，新加坡食品局（SFA）也发布公告，召回两批次婴幼儿配方奶粉，其中包括另一家法国食品企业旗下的多美滋婴儿配方奶粉。 1月22日，海关总署发布消费提示称，目前我国暂未发现兰特黎斯（Lactalis）旗下召回的Picot品牌婴幼儿配方奶粉进口记录。海关总署进出口食品安全局提 醒消费者，请立即停止使用个人通过携带、代 ...

Core Viewpoint - Junlebao Dairy Group is preparing for an IPO in Hong Kong, aiming to become a leading player in the Chinese dairy market, following its competitors' moves to list on various exchanges [1][17]. Group 1: Company Overview - Junlebao is positioned as the third-largest comprehensive dairy company in China, with projected revenues of nearly 20 billion RMB in 2024, following Yili and Mengniu [1][19]. - The company has established an integrated supply chain covering dairy farming, product innovation, production, and sales [4][19]. - Junlebao operates 33 modern dairy farms across several provinces, with a dairy cow population of approximately 192,000, leading to a self-sufficiency rate of 66% for raw milk [6][19]. Group 2: Market Position and Competition - The dairy market in China is highly competitive, with Yili and Mengniu holding market shares of 24.6% and 18.7% respectively, while Junlebao holds a 4.3% market share [2][19]. - In the infant formula segment, Junlebao ranks fifth with a 5% market share, competing against major players like Yili and Feihe [2][19]. Group 3: Financial Performance - Junlebao's revenue for 2023, 2024, and the first nine months of 2025 is approximately 17.55 billion RMB, 19.83 billion RMB, and 15.13 billion RMB respectively, with net profits of 5.58 million RMB, 1.12 billion RMB, and 902 million RMB [11][12]. - The company has seen a decline in its milk powder revenue share from 30.9% to 22.1% over the reporting period, while liquid milk products have increased from 55.1% to 61.1% [10][11]. Group 4: Sales and Distribution - Junlebao relies heavily on third-party distributors, with over 74% of its revenue coming from this channel during the reporting period [9][19]. - The company utilizes both offline and online sales channels, including major supermarkets and e-commerce platforms [3][9]. Group 5: Future Plans and Use of IPO Proceeds - The funds raised from the IPO will be used for expanding production facilities, enhancing brand marketing, supporting market development, and improving research and development capabilities [18][19].

Market Overview - A-shares showed significant selling pressure towards the end of the trading session, with the Shanghai Composite Index closing up 0.08% at 4116.94 points, the Shenzhen Component rising 0.7%, and the ChiNext Index increasing by 0.54%[1] - The Hong Kong Hang Seng Index rose 0.37% to 26585.06 points, with the Hang Seng Tech Index up 1.11% and the Hang Seng China Enterprises Index up 0.31%[1] - The total market turnover in Hong Kong was 2504.514 million HKD[1] International Developments - U.S. stock indices closed higher, with the Dow Jones up 1.21%, the S&P 500 rising 1.16% to 6875.62 points, and the Nasdaq increasing by 1.18%[1] - President Trump announced a framework agreement regarding Greenland, retracting the threat of tariffs on eight European countries, which led to a rebound in U.S. stock, bond, and currency markets[1][13] - U.S. Treasury Secretary Becerra expressed anticipation for a quick meeting with Chinese Vice Premier He Lifeng to discuss economic agreements[1][13] Trade Relations - The European Parliament indefinitely postponed the vote on the U.S.-EU trade agreement until the U.S. returns to a cooperative stance, following Trump's threats regarding tariffs[13] - The European Commission is considering countermeasures against U.S. goods worth 930 billion euros (approximately 1.09 trillion USD) if necessary[13] Corporate Developments - China Galaxy received approval from the China Securities Regulatory Commission to issue up to 5 billion RMB in technology innovation bonds[15] - Huatai Securities raised 7.5 billion RMB through the issuance of subordinated bonds, with a minimum coupon rate of 1.99%[15] - The PCB equipment manufacturer Dazhu CNC reported a 144% year-on-year increase in net profit for the first ten months of the previous year[11]

法国乳制品企业拉克塔利斯公司21日宣布，在法国、中国、西班牙、澳大利亚等18个国家和地区召回多个批次的婴幼儿奶粉，原因是相关产品可能含有蜡 样芽孢杆菌毒素，存在引发腹泻和呕吐等风险。 拉克塔利斯公司当天在一份声明中说，此次召回是根据法国婴幼儿营养专业协会的相关警告做出的"谨慎决定"。声明说，在对复原产品开展的进一步检测 中发现，产品中可能存在有关毒素。 声明表示，截至目前，法国相关部门尚未收到食用涉事产品后发生不良反应的报告。 近期，全球多起婴幼儿奶粉召回事件引发乳制品行业关注，原因均与产品可能含有蜡样芽孢杆菌毒素有关。新加坡食品局本月17日已宣布召回法国食品企 业达能旗下多美滋婴儿配方奶粉。本月初，雀巢在欧洲的多家子公司也宣布召回在不同市场销售的部分批次婴幼儿配方奶粉。 英国食品标准局日前在一份食品安全警报中介绍，蜡样芽孢杆菌高度耐热，在烹饪、使用沸水或冲调婴儿奶粉的过程中难以灭活。这种细菌可能引发食物 中毒，且症状可能迅速出现，包括恶心、呕吐、胃部痉挛等。 来源：新华社 记者： 崔可欣 关注" 新华网财经 "视频号 更多财经资讯等你来看 往期推荐 机器人将再度登上央视春晚！ 马斯克，索赔1340亿美元 N ...

Core Viewpoint - Sunshine Dairy (001318.SZ) announced a change in shareholding that triggered a shift in ownership percentages, with major shareholder Nanchang Zhihe reducing its stake from 72.74% to 70.00% [1] Group 1: Shareholding Changes - Nanchang Zhihe and its concerted party, Jiangxi Sunshine Dairy Group, reduced their holdings from 205.60 million shares to 197.86 million shares, representing a decrease of 5% in ownership [1] - Nanchang Zhihe plans to increase its stake by acquiring 3,686,900 shares (1.30% of total shares) from February 6, 2024, to July 9, 2024, and subsequently sell the same amount from June 27, 2025, to September 2, 2025 [1] - Nanchang Zhihe intends to further reduce its holdings by 7,738,000 shares (2.74% of total shares) between January 9, 2026, and January 20, 2026 [1] Group 2: Financial Data - The weighted average price of Sunshine Dairy shares was 15.719 yuan during the period of Nanchang Zhihe's share reduction, resulting in a total reduction amount of approximately 122 million yuan [2] - During the period from June 27, 2025, to September 2, 2025, the weighted average price was 14.840 yuan, leading to a reduction amount of approximately 54.71 million yuan for Jiangxi Sunshine Dairy Group [2] - Sunshine Dairy was listed on the Shenzhen Stock Exchange on May 20, 2022, with a public offering of 70.70 million shares at a price of 9.46 yuan per share, raising a total of 668.82 million yuan [2]

Group 1 - The 2026 Functional Food Health Summit (FFWS 2026) was held in Bangkok, Thailand, gathering over 150 industry leaders from more than 20 countries to discuss topics such as technological innovation [1] - The summit awarded 10 prizes to Feihe for its outstanding product innovation and research capabilities, making it one of the most awarded companies at the event [1][2] - Feihe's recognition signifies its evolution from a leader in infant formula to a comprehensive provider of all-age nutritional solutions, contributing to healthier and longer lives with "Chinese solutions" [2] Group 2 - Feihe's Vice President and Research Institute Director, Zhang Xuguang, emphasized the company's commitment to unlocking a new era of lifecycle nutrition through market-driven integrated research and development [4] - The company focuses on innovative solutions for different age groups and specific health needs, enhancing its research in basic, functional, and specialized nutrition [4][12] - Feihe's product matrix includes innovations in infant formula, functional ingredients, and specialized foods, showcasing its comprehensive approach to lifecycle nutrition [6][15] Group 3 - Feihe's award-winning products include the "Breast Milk Affinity Formula Technology Innovation Award" and "Outstanding Early Life Nutrition Award," reflecting their alignment with infant physiological needs [8] - The company also received accolades for its liquid milk protein and products launched in Southeast Asia, demonstrating its international technological innovation capabilities [9] - Feihe's advancements in fresh nutrition and its commitment to quality have positioned it as a leader in the global functional food industry [12] Group 4 - Feihe has established a fresh raw material traceability system, enhancing transparency in the supply chain and allowing consumers to verify the origins of ingredients [13] - The company has been a pioneer in the dairy industry, implementing an integrated supply chain model and setting new standards for fresh milk technology [12] - Feihe's lifecycle nutrition strategy encompasses a wide range of products, from infant formula to specialized nutrition for the elderly, ensuring comprehensive health support [15]

Core Insights - The 2026 Functional Food Health Summit (FFWS 2026) held in Bangkok, Thailand, gathered over 150 industry leaders from more than 20 countries to discuss technological innovations in the functional food sector [1][3] - Feihe won a total of 10 awards at the summit, recognizing its outstanding product innovation and research capabilities across various fields, including infant nutrition and functional ingredients [1][3] Group 1: Awards and Recognition - Feihe received recognition as one of the most awarded companies at the summit, highlighting its transition from a leader in infant formula to a comprehensive provider of all-age nutrition [3][10] - The awarded products included Feihe's infant formula and functional foods, which were acknowledged for their scientific solutions to early-life nutrition and health needs [12][18] Group 2: Innovation and Strategy - Feihe's Vice President, Zhang Xuguang, emphasized the company's commitment to unlocking a new era of lifecycle nutrition through market-driven integrated research and development [10][22] - The company has established a comprehensive product matrix that addresses nutritional needs from infancy to old age, showcasing its technological advancements and commitment to quality [27][22] Group 3: Product Highlights - Specific awards included the "Breast Milk Affinity Formula Technology Innovation Award" and the "Active Immune Protein Excellence Product Award," reflecting Feihe's focus on tailored nutrition for different age groups [12][18] - Feihe's liquid milk protein was recognized for its innovative raw material technology, marking it as the only company to receive an award in this category [18][22] Group 4: Future Directions - Feihe plans to continue its focus on lifecycle functional nutrition, leveraging its full supply chain advantages and technological innovations to drive high-quality development in the functional food industry [27][22] - The company has introduced a fresh raw material traceability system, enhancing transparency in the supply chain and ensuring product safety and freshness for consumers [23][22]

Investment Rating - The industry is rated as "Buy" with expectations of returns exceeding the market benchmark index by more than 15% over the next 6-12 months [6]. Core Insights - The report highlights the strong growth potential of low-temperature liquid dairy products, with the company positioning itself as a leading brand in segmented markets. The company has successfully expanded its product matrix and is focusing on nationwide market penetration [1][2][3]. - The company has demonstrated robust single product development capabilities, with its core brands becoming leaders in their respective segments. The introduction of innovative products like "Jianchun" and "Yuexianhuo" has significantly contributed to its market share growth [3][48]. - The company is actively optimizing its distribution channels, with a significant portion of revenue coming from its distribution network. The company is also exploring new retail channels and B2B opportunities to enhance its market presence [4][50]. Summary by Sections Industry Overview - The dairy product industry in China is experiencing steady growth, with the terminal market size projected to reach 6,535 billion yuan by 2024, growing at a CAGR of 1.8% from 2019 to 2024. Liquid milk accounts for 54% of this market [14][15]. - Low-temperature liquid milk is expected to grow at a faster rate compared to room temperature milk, with a projected market size of 897 billion yuan by 2024, reflecting a CAGR of 3% [15][23]. Company Profile - The company, established in 2000, has diversified its product offerings, including high-end yogurt, infant formula, and fresh milk. It has become a top brand in low-temperature yogurt and high-end fresh milk by 2024 [1][32]. - The company reported a revenue of 198 billion yuan in 2024, with a year-on-year growth of 13%. For the first three quarters of 2025, revenue grew by 2% [38][42]. Product and Revenue Breakdown - The company's revenue structure shows that liquid milk and infant formula are the main categories, with low-temperature yogurt being the largest sub-category. In Q1-Q3 2025, liquid dairy products accounted for 87% of total revenue [42][43]. - Low-temperature yogurt and fresh milk revenues showed resilience, with fresh milk revenue growing by 41% year-on-year [2][42]. Market Expansion and Distribution - The company is expanding its national sales network, having acquired regional brands to strengthen its presence in the northwest and southwest markets. Key regions like North China are projected to contribute significantly to revenue [5][57]. - The distribution model is primarily based on a dealer network, which accounted for approximately 69% of revenue in Q1-Q3 2025. The company is also enhancing its online and direct sales channels [4][50]. Financial Performance - The company has shown improved profitability, with adjusted net profits reaching 11.6 billion yuan in 2024, a 92% increase year-on-year. The gross margin has also improved, indicating better operational efficiency [38][40].